The table below shows HALOZYME THERAPEUTICS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$651.56M
$479.06M
$388.57M
$240.11M
$299.44M
$55.45M
Capital expenditure
$6.97M
$10.70M
$15.29M
$4.81M
$1.46M
$2.50M
Investing cash flow
-$545.81M
-$262.72M
-$96.91M
-$487.00M
-$406.29M
$78.35M
Dividends paid
-
-
-
-
-
-
HALO operating cash flow (10-K history)
HALOZYME THERAPEUTICS, INC. reported operating cash flow of $651.56M for fiscal year 2025. That is up 36.0% from $479.06M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$50.38M (FY 2016) to $651.56M. Figures come from the company's audited annual reports as filed with the SEC.
